Press release - March 5, 2026

RSM, the 6th largest global network of audit, accounting and consulting firms, performed the buy-side financial due diligences for Efor Group, a recognized consulting firm specializing in Life Sciences, in connection with the acquisition of DynamixE, a U.S.-based engineering company specializing in Commissioning, Qualification and Validation (CQV) services for the biopharmaceutical and life sciences industries, as well as in connection with the acquisition of No deviation, a Singapore-based consulting and advisory firm serving the pharmaceutical industry.

Efor Group was supported on both transactions by an RSM team led by partner Eric Fougedoire.

Following the acquisition of Project Delivery Partners, this represents the second external growth transaction entrusted to RSM's Corporate Finance practice by the Group

Through these transactions, RSM’s Corporate Finance team further strengthens its expertise in supporting Life Sciences and regulatory consulting players in cross-border build-up strategies with end-to-end advisory support.

Paris, March 5, 2026
Official press release from Efor

Efor announces the acquisition of DynamixE in the United States and No deviation in Singapore. Executed simultaneously, these transactions mark a new phase in the acceleration of its international expansion and reflect a clear ambition: to build a global leader in quality and compliance dedicated to the healthcare industries.

A Strategic Move in Two Key Markets

With these acquisitions, Efor strengthens its presence in the most decisive regions of the global pharmaceutical industry: the United States, the world’s largest market, and Asia, a key region capturing an increasing share of global investment.

In the United States, the integration of DynamixE enhances the Group’s technical capabilities and its ability to deliver complex industrial projects. Founded in New York in 2017 and established in major U.S. biopharmaceutical hubs, the company has built a strong reputation as a methodological leader through its comprehensive Commissioning, Qualification & Validation (CQV) programs and its recognized expertise in process engineering and automation

“The integration of DynamixE accelerates our U.S. trajectory, already driven by strong growth momentum in the region. It reinforces our footprint in the United States and clearly reflects our ambition to become a leading player in this market, ” said Mathieu Roger, CEO and Founder of Efor.

In Asia, the addition of No deviation is designed to further strengthen the Group’s regional foothold, which has already grown significantly in recent months. Based in Singapore, a major regional hub, the company reinforces Efor’s presence across Asia. With more than 300 employees now operating in the region, the Group is strengthening its position in key Asian markets, particularly China.

“Asia is a strategic pillar of our global development. With No deviation, we are consolidating our leadership in Singapore and accelerating our expansion across the continent. Asia is a strategic market, and we intend to strengthen our presence there over the long term, ” added the Group’s CEO.

A clear global ambition

Since its founding in Lyon in 2013, Efor has experienced rapid growth, combining organic expansion with targeted acquisitions. With more than 3,000 employees and operations in 18 countries, the Group supports 90% of the global leaders in the pharmaceutical sector and generated €340 million in revenue in 2025.

Following the successive integrations of PharmEng Technology, Project Delivery Partners (PDP), and Process Engineering Specialists (PES) in 2025, Efor now operates with a global organization supported by a strong local footprint. This hybrid model — combining agility and proximity with the strength of a structured international player — represents a distinctive positioning and enables the Group to respond quickly to strategic industrial investment projects.

Its strategy is to establish the Group sustainably among the global leaders in quality and compliance by strengthening its presence in the world’s main industrial hubs, where production capacity and therapeutic innovation are concentrated.

A Value Proposition at the Heart of Industry Transformation

Le secteur des Life Sciences connaît une transformation profonde. L’essor des biothérapies, The Life Sciences sector is undergoing profound transformation. The rise of biotherapies, the expansion of manufacturing capacity, and increasingly stringent regulatory requirements are redefining industrial standards.

In this environment, reliability and speed of industrial commissioning have become critical. Efor supports manufacturers in securing their infrastructure, anticipating regulatory constraints, and accelerating access to safe treatments. The Group operates at the very heart of major international laboratories’ facilities, helping transform scientific innovation into compliant and fully operational production capabilities.

By strengthening its presence simultaneously in North America and Asia - alongside Europe, the historical foundation of its development - Efor is consolidating a structured global footprint and reaffirming its ability to operate at the center of the world’s largest industrial investments